Search academic texts

Information × Registration Number 0216U001139, 0114U001063 , R & D reports Title To optimize the treatment of patients with "triple negative "metastatic breast cancer popup.stage_title Head Syvak Lyubov Andriyivna, Registration Date 25-01-2016 Organization National Cancer Institute popup.description2 Object of study - 42 metastatic triple negative breast cancer patients, who were administered chemotherapy with САР and ТС regimens. Aim of the study -to increase the efficacy of the treatment of metastatic triple negative breast cancer patients by using of the most effective chemotherapy regimens based on clinical and laboratory prognostic factors and individual sensitivity to chemotherapy drugs. Methods of study and equipment: clinical, laboratory, instrumental, statistical; US apparatus "Aloca", hematologic analyzer ВС-3000, chemistry analyzer "Vitros", spectrophotometer "Thermo", high speed centrifuge "Biofuge", thermostate "Termit". As a result of combined clinical (complaints, physical data), laboratory (common blood count, blood chemistries, urinalysis), instrumental (ECG, echocardiography, chest x-ray, abdominal ultrasound or CT of the chest, abdomen and pelvis with contrast enhancement) research and analysis of molecular genetic parameters (gene polymorphism GSTP1, MTHFR, protein expression ITSN2) during chemotherapy for standard regimens CAP and TC (4-6 cycles) in patients with metastatic triple negative breast cancer found that regimens have moderate (II-III grade) toxicity, the main manifestations of which were gastrointestinal (91.2% and 87.6%) and hematological (68 4% and 71.2%). The dependence of the effectiveness of chemotherapy (by RECIST criteria) was assessed by initial level of total proteolytic activity of peripheral blood (SPPC). Patients who achieved complete or partial regression of the tumor the average level of SPPC was significantly higher (1,05 ± 9,77); p<0.001, in the case of the stabilization process is significantly lower (0,43 ±0,058); p<0.001, and with the progression of the disease is determined the low level (0,03±0,05, p<0.001). The influence of infiltration of tumor stroma by lymphoid cells СD3+, CD4+ and CD8+ on the effectiveness of chemotherapy in metastatic triple negative breast cancer. It is determined that the degree of pathomorphosis was significantly correlated with a marker of proliferative activity Ki-67 and the level of infiltration of the tumor cells CD8+ (p=0.02 and p=0.04 respectively). Progression free period was associated with high levels of CD8+ lymphocytes in the stroma residual tumor (r=0.53, p=0,075); in short - with a high level of Ki-67 (r=0,37, p<0,1). Product Description popup.authors А.Аскольський М. Кліманов Н. Касап Н. Майданевич Н.Верьовкіна С. Лялькін popup.nrat_date 2020-04-02 Close